Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer

Table 3 Univariate regressions of significant predictive or prognostic factors in resectable locally advanced gastroesophageal cancer patients

Poisson regression	Relative risk (95%CI)	Hazard ratio (95%CI)	P value
T stage regression between LMR groups
> 3.56/≤ 3.56	1.42 (1.01-1.99)		0.043
Progression between PLR groups
> 141/≤ 141	2.17 (0.89-5.26)		0.088
Mortality between PLR groups
> 144/≤ 144	1.53 (0.92-2.55)		0.103
Cox regression
NLR		1 (0.97-1.0)	0.972
Patients without pCR		2.1 (0.8-5.2)	0.129
Patients without (pathological) tumor regression		2.8 (1.6-5)	< 0.001
Patients without T stage regression		2.1 (1.1-3.9)	0.017

CI: Confidence interval; FLOT: Fluorouracil plus leucovorin, oxaliplatin, and docetaxel; LMR: Lymphocyte-to-monocyte ratio; NLR: Neutrophile-to-lymphocyte ratio; pCR: Pathological complete response; PLR: Platelet-to-lymphocyte ratio; preFLOT: Preoperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel; TRG: Tumor regression grade.